Justin L Sewell1, Fernando S Velayos. 1. Center for Innovation in Access and Quality, Division of Gastroenterology and Hepatology, San Francisco General Hospital, Department of Medicine, University of California San Francisco, San Francisco, California 94143, USA.
Abstract
BACKGROUND: Race and socioeconomic status (SES) significantly affect the content and delivery of healthcare for multiple chronic disease states. Inflammatory bowel disease (IBD) is a set of complex, chronic diseases with the potential for significant morbidity if the content or delivery of healthcare is suboptimal. However, the literature related to race, SES, and IBD remains fragmented. METHODS: Using guidelines published by the Centre for Reviews and Dissemination, we performed a systematic review of the world's literature to identify studies related to: 1) IBD, 2) race/ethnicity, 3) SES, 4) healthcare delivery, and 5) healthcare effectiveness. RESULTS: We identified 40 studies that met inclusion criteria. Twenty-four studies (60%) assessed the role of SES and 21 (53%) evaluated race. Topics addressed by these studies included: 1) Utilization of Medical and Surgical Therapy; 2) Adherence to Medical Therapy; 3) Clinical Outcomes; 4) Healthcare Access and Utilization; 5) Disease Perception and Knowledge; and 6) Employment/Insurance. We identified race- and SES-based disparities in the content of medical and surgical healthcare, utilization of inpatient and ambulatory medical care, adherence to medical therapy, and disease perceptions and knowledge. Several studies also identified race- and SES-based disparities in outcomes for IBD, including in-hospital mortality rates and health-related quality of life. CONCLUSIONS: Race- and SES-based disparities in the delivery and effectiveness of healthcare for patients with IBD exist in numerous domains, yet studies remain limited in their scope and breadth. Concerted, prospective, multicenter efforts are needed to address underlying causes for disparities and to identify methods of reducing and eliminating disparities.
BACKGROUND: Race and socioeconomic status (SES) significantly affect the content and delivery of healthcare for multiple chronic disease states. Inflammatory bowel disease (IBD) is a set of complex, chronic diseases with the potential for significant morbidity if the content or delivery of healthcare is suboptimal. However, the literature related to race, SES, and IBD remains fragmented. METHODS: Using guidelines published by the Centre for Reviews and Dissemination, we performed a systematic review of the world's literature to identify studies related to: 1) IBD, 2) race/ethnicity, 3) SES, 4) healthcare delivery, and 5) healthcare effectiveness. RESULTS: We identified 40 studies that met inclusion criteria. Twenty-four studies (60%) assessed the role of SES and 21 (53%) evaluated race. Topics addressed by these studies included: 1) Utilization of Medical and Surgical Therapy; 2) Adherence to Medical Therapy; 3) Clinical Outcomes; 4) Healthcare Access and Utilization; 5) Disease Perception and Knowledge; and 6) Employment/Insurance. We identified race- and SES-based disparities in the content of medical and surgical healthcare, utilization of inpatient and ambulatory medical care, adherence to medical therapy, and disease perceptions and knowledge. Several studies also identified race- and SES-based disparities in outcomes for IBD, including in-hospital mortality rates and health-related quality of life. CONCLUSIONS: Race- and SES-based disparities in the delivery and effectiveness of healthcare for patients with IBD exist in numerous domains, yet studies remain limited in their scope and breadth. Concerted, prospective, multicenter efforts are needed to address underlying causes for disparities and to identify methods of reducing and eliminating disparities.
Authors: Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein Journal: Gastroenterology Date: 2008-09-17 Impact factor: 22.682
Authors: Geoffrey C Nguyen; Theodore M Bayless; Neil R Powe; Thomas A Laveist; Steven R Brant Journal: Inflamm Bowel Dis Date: 2007-11 Impact factor: 5.325
Authors: Michael D Kappelman; Sheryl L Rifas-Shiman; Ken Kleinman; Dan Ollendorf; Athos Bousvaros; Richard J Grand; Jonathan A Finkelstein Journal: Clin Gastroenterol Hepatol Date: 2007-09-29 Impact factor: 11.382
Authors: Somnath Saha; Michele Freeman; Joahd Toure; Kimberly M Tippens; Christine Weeks; Said Ibrahim Journal: J Gen Intern Med Date: 2008-02-27 Impact factor: 5.128
Authors: Leigh F Callahan; Jack Shreffler; Thelma J Mielenz; Jay S Kaufman; Britta Schoster; Randy Randolph; Philip Sloane; Robert DeVellis; Morris Weinberger Journal: Prev Chronic Dis Date: 2008-12-15 Impact factor: 2.830
Authors: Samuel R Montgomery; Paris D Butler; Chris J Wirtalla; Karole T Collier; Rebecca L Hoffman; Cary B Aarons; Scott M Damrauer; Rachel R Kelz Journal: Am J Surg Date: 2018-05-12 Impact factor: 2.565
Authors: Edward L Barnes; Bharati Kochar; Millie D Long; Joel Pekow; Ashwin Ananthakrishnan; Adjoa Anyane-Yeboa; Christopher Martin; Joseph Galanko; Hans H Herfarth; Michael D Kappelman; Robert S Sandler Journal: Inflamm Bowel Dis Date: 2018-11-29 Impact factor: 5.325
Authors: Drew J Gunnells; Melanie S Morris; Aerin DeRussy; Allison A Gullick; Talha A Malik; Jamie A Cannon; Mary T Hawn; Daniel I Chu Journal: J Gastrointest Surg Date: 2016-01-07 Impact factor: 3.452
Authors: Briton Lee; Edward W Holt; Robert J Wong; Justin L Sewell; Ma Somsouk; Mandana Khalili; Jacquelyn J Maher; Michele M Tana Journal: Autoimmunity Date: 2018-06-11 Impact factor: 2.815